MX2024010608A - Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. - Google Patents

Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.

Info

Publication number
MX2024010608A
MX2024010608A MX2024010608A MX2024010608A MX2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A
Authority
MX
Mexico
Prior art keywords
disorder
macro
medium
substituted heterocycle
related uses
Prior art date
Application number
MX2024010608A
Other languages
English (en)
Spanish (es)
Inventor
Gregory R Ott
Matthew Spendiff
Karl Gibson
Paul Humphries
Bruce Lefker
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of MX2024010608A publication Critical patent/MX2024010608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2024010608A 2022-03-01 2023-03-01 Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. MX2024010608A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US202363439477P 2023-01-17 2023-01-17
PCT/US2023/014275 WO2023167925A1 (en) 2022-03-01 2023-03-01 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Publications (1)

Publication Number Publication Date
MX2024010608A true MX2024010608A (es) 2024-09-23

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010608A MX2024010608A (es) 2022-03-01 2023-03-01 Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.

Country Status (12)

Country Link
US (2) US20250236629A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486748A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507852A (cg-RX-API-DMAC7.html)
KR (1) KR20240157067A (cg-RX-API-DMAC7.html)
CN (1) CN119110802A (cg-RX-API-DMAC7.html)
AU (1) AU2023228830A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245204A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002576A1 (cg-RX-API-DMAC7.html)
IL (1) IL315237A (cg-RX-API-DMAC7.html)
MX (1) MX2024010608A (cg-RX-API-DMAC7.html)
TW (1) TW202400606A (cg-RX-API-DMAC7.html)
WO (1) WO2023167925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
CN116635393A (zh) * 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途

Also Published As

Publication number Publication date
KR20240157067A (ko) 2024-10-31
TW202400606A (zh) 2024-01-01
US20250289828A1 (en) 2025-09-18
JP2025507852A (ja) 2025-03-21
CL2024002576A1 (es) 2025-01-10
EP4486748A1 (en) 2025-01-08
AU2023228830A1 (en) 2024-09-12
CA3245204A1 (en) 2023-09-07
CN119110802A (zh) 2024-12-10
US20250236629A1 (en) 2025-07-24
WO2023167925A1 (en) 2023-09-07
IL315237A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
WO2022051596A8 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CL2024002576A1 (es) Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
WO2012045883A1 (en) Cyclopropylamine inhibitors of oxidases
BR112020010429A2 (pt) uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
NO20075353L (no) Forbindelser, isomerer og farmasoytisk akseptable salter derav, som vanilloidreseptorantagonister, og farmasoytiske preparater inneholdende slike
KR20170108887A (ko) NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
BR112019016248A2 (pt) piridinas substituídas com hidrocarbilssulfonila e uso das mesmas no tratamento de câncer
BR112019016233A2 (pt) piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer
JP7600131B2 (ja) 神経系疾患の予防または治療用薬学的組成物
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CZ111897A3 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
CA2792913A1 (en) Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
EP3836912B1 (en) Combinations of substituted benzamides and 5-asa agents
EP2668159A1 (en) 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
EP4061371B1 (en) Masitinib for the treatment of sickle cell disease
CA3201259A1 (en) Masitinib for the treatment of alzheimer's disease
MX2023004623A (es) Moduladores de la via integrada de respuesta al estres.
WO2024151519A3 (en) Pparg modulators
MX2024013549A (es) Heterociclos novedosos, métodos de preparación y usos de los mismos
BR112022008265A2 (pt) Composições farmacêuticas contendo diácido de oligossacarídeo de alginato
HK40050156B (en) Co-crystal of sorafenib derivatives and process for preparation thereof
WO2025178571A1 (en) Anti-non-tuberculous mycobacteria inhibitors
EP4351574A1 (en) Inhibitors of ttbk1